Introduction
IL-12 is a heterodimeric cytokine bridging innate resistance and antigen-specific adaptive immunity (1). IL-12 is produced predominantly by professional APCs and serves as an important regulator of T cell and NK cell function (2, 3). IL-12 has a powerful antitumor activity related to both IFN-γ-dependent and -independent mechanisms (4-9).
Numerous effects of IL-12 on human B cells from normal individuals have been reported, such as induction of proliferation and differentiation to Ig-secreting cells (10), upregulation of IL-18R (11), and induction of IFN-γ mRNA and protein (11-13).
The biological functions of human IL-12 are mediated by the heterodimeric IL-12R composed of two subunits, the β1 and the β2 chains, conferring high-affinity binding of and responsiveness to 15) . The β1 chain participates in the formation of the IL-23 receptor, whereas the β2 chain is an unique component of IL-12R (1). The IL-12Rβ2 gene maps on chromosome 1p31.2 and is composed of 16 introns and 16 exons, the first of which is not transcribed (15).
We have previously shown that human lymphoblastoid B cell lines (LCLs) and Burkitt lymphoma (BL) cell lines express constitutively IL-12Rβ1 mRNA but lack IL-12Rβ2 mRNA (16). In contrast, normal human naive, germinal center (GC), and memory B cells express constitutively the transcripts of both IL-12R genes (11). These findings led us to speculate that malignant B cells could benefit from the silencing of the IL-12Rβ2 gene.
Here we first investigated IL-12R gene expression in primary tumor cells from patients with different chronic B cell lymphoproliferative disorders representing the postulated counterparts of the major mature B cell subsets, as no information was available on this issue. IL-12Rβ2 mRNA expression was not detected in any sample. Second, we studied the mechanism(s) involved in and the functional consequences of the silencing of this gene in human primary neoplastic B cells, as well as in transformed B cell lines. Our findings support the conclusion that the IL-12Rβ2 gene functions as tumor suppressor in a wide spectrum of human B cell malignancies. Figure 1A shows one experiment, representative of the ten performed with identical results, in which the IL-12Rβ1 and β2 transcripts were detected in naive, GC, and memory B cells isolated from tonsil, consistently with a previous study (11). As is apparent, these B cell fractions expressed CD19, but not CD3γ, CD56, or CD68, mRNA.
Results

Expression of IL-12R in normal tonsil B cell subsets and in malignant B cells from different human chronic lymphoproliferative disorders.
In subsequent studies, frozen tonsil tissue sections were stained sequentially with phycoerythrin-conjugated (PE-conjugated) anti-IL-12Rβ2 and FITC-conjugated CD19 mAb's or isotype and fluorochrome matched control mAb's and then with DAPI. Images were acquired using either a filter selective for fluorochrome (Figure 1 , C, G, K and D, H, L) or a triple-band -i.e., DAPI, PE, and FITC-specific -filter (Figure 1 , E, I, M and F, J, N). Figure 1B shows a DAPI staining with the follicular mantle (FM), the GC, and the subepithelial (SE) area in boxes. Figure 1 , C, G, K and D, H, L, shows staining with CD19 (green) or anti-IL-12Rβ2 (red) mAb's, respectively. As is apparent, the large majority of cells positioned in the FM, GC, and SE areas expressed CD19
